Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

316 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The role of relative lymphocyte count as a biomarker for the effect of catumaxomab on survival in malignant ascites patients: results from a phase II/III study.
Heiss MM, Ströhlein MA, Bokemeyer C, Arnold D, Parsons SL, Seimetz D, Lindhofer H, Schulze E, Hennig M. Heiss MM, et al. Among authors: hennig m. Clin Cancer Res. 2014 Jun 15;20(12):3348-57. doi: 10.1158/1078-0432.CCR-13-2351. Epub 2014 Apr 8. Clin Cancer Res. 2014. PMID: 24714773 Clinical Trial.
Immunotherapy of peritoneal carcinomatosis with the antibody catumaxomab in colon, gastric, or pancreatic cancer: an open-label, multicenter, phase I/II trial.
Ströhlein MA, Lordick F, Rüttinger D, Grützner KU, Schemanski OC, Jäger M, Lindhofer H, Hennig M, Jauch KW, Peschel C, Heiss MM. Ströhlein MA, et al. Among authors: hennig m. Onkologie. 2011;34(3):101-8. doi: 10.1159/000324667. Epub 2011 Feb 18. Onkologie. 2011. PMID: 21358214 Clinical Trial.
Immunomonitoring results of a phase II/III study of malignant ascites patients treated with the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3).
Jäger M, Schoberth A, Ruf P, Hess J, Hennig M, Schmalfeldt B, Wimberger P, Ströhlein M, Theissen B, Heiss MM, Lindhofer H. Jäger M, et al. Among authors: hennig m. Cancer Res. 2012 Jan 1;72(1):24-32. doi: 10.1158/0008-5472.CAN-11-2235. Epub 2011 Nov 1. Cancer Res. 2012. PMID: 22044753 Clinical Trial.
Phase II study of weekly oxaliplatin plus infusional fluorouracil and folinic acid (FUFOX regimen) as first-line treatment in metastatic gastric cancer.
Lordick F, Lorenzen S, Stollfuss J, Vehling-Kaiser U, Kullmann F, Hentrich M, Zumschlinge R, Dietzfelbinger H, Thoedtmann J, Hennig M, Seroneit T, Bredenkamp R, Duyster J, Peschel C. Lordick F, et al. Among authors: hennig m. Br J Cancer. 2005 Jul 25;93(2):190-4. doi: 10.1038/sj.bjc.6602697. Br J Cancer. 2005. PMID: 16012522 Free PMC article. Clinical Trial.
316 results